M&A activity remains high despite Covid-19, with mega-deals boosting deal value

Covid-19
M&A deals are a core driver of growth in the Bio/Pharma industry, and it seems that the impact of COVID-19 has not hindered deal-making as much as may have been expected in 2020. Credit: Shutterstock.